Sign In
Buy MRTX
$58.70
+0 (+0%)
At Close: Apr 19, 2024
Mirati Therapeutics: Another Growth Cycle Approaching
06:56am, Friday, 30'th Apr 2021
Mirati Therapeutics: Another Growth Cycle Approaching
SAN DIEGO, April 10, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced initial preclinical results evaluating its investigational s
This 2020 Biotech IPO Is Poised to Break Out in 2021
06:15am, Friday, 02'nd Apr 2021
Revolution Medicines' leading compound is shaping up to be a platform in a pill.
Mirati Therapeutics Board Elects Shalini Sharp as New Independent Director
07:30am, Wednesday, 31'st Mar 2021
SAN DIEGO, March 31, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced its Board of Directors has elected a new independent direct
Mirati (MRTX) Down 15.7% Since Last Earnings Report: Can It Rebound?
12:41pm, Saturday, 27'th Mar 2021
Mirati (MRTX) reported earnings 30 days ago. What's next for the stock?
7 Biotech Stocks With Catalysts That Go Far Beyond Covid-19 Vaccines
11:54am, Friday, 12'th Mar 2021
If you think ecommerce and digital banking have accelerated in the past year, then you really need to check out promising biotech stocks. The post 7 Biotech Stocks With Catalysts That Go Far Beyond Co
SAN DIEGO, March 10, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced it will present initial preclinical data on the Company's
Why Turning Point Is Turning Heads
10:59am, Tuesday, 23'rd Feb 2021
This oncology biotech is up over 450% since its April 2019 IPO. Are there still gains to come, or should investors turn away?
Mirati Therapeutics To Present At The 39th Annual J.P. Morgan Healthcare Conference
05:19pm, Monday, 04'th Jan 2021
SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 39th Annual J.P. Morgan Healthcare Conference in San F
Mirati Therapeutics: A Gift That Keeps On Giving
09:11am, Thursday, 31'st Dec 2020
Leveraging sound science and prudent cancer treatment, Mirati is growing robustly. The two lead drugs (sitravatinib and Adagrasib) are rapidly advancing for different cancer indications.
7 Biotech Stocks To Buy Beyond Covid Vaccine Plays
01:37pm, Monday, 14'th Dec 2020
It's a relief to know Covid-19 vaccines are on the way. But there are plenty of other great biotechs that have been overlooked in the market frenzy.
Mirati Therapeutics To Participate In The 2020 Evercore ISI HealthCONx Conference
04:30pm, Monday, 23'rd Nov 2020
SAN DIEGO, Nov. 23, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced they will participate in a fireside chat at the 2020 Ever
SAN DIEGO, Oct. 30, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the closing of its previously announced underwritten public offering of 4,985,706 shares of its common
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
08:04pm, Tuesday, 27'th Oct 2020
SAN DIEGO, Oct. 27, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 4,335,397 shares of its common stock at a price to t
Mirati Shares Hit Record High on Cancer Study Results
02:11pm, Tuesday, 27'th Oct 2020
Promising results from a study of its cancer drug pushed Mirati Therapeutics Inc. (NASDAQ:MRTX) to an all-time high Monday. Shares of the San Diego-based biotech hit more than $210 and are at about $2
